Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Classic Psychedelic

or [[:Category:Anti-inflammatories|Anti-inflammatory]]

Use the filters below to narrow your results.

Other values:

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Irreversible non-selective MAO inhibitor (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · None (2) · Contains LSA (2) · Contains mescaline (2) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

None (88) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1) · '"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)

None (88) · 25 mg (1) · Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) · Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)

None (88) · 0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1)

None (88) · 1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors (1) · 200 mg/d (1) · Formulation-specific; ~4.8 g/d typical maximum oral (1)

None (86) · Oral (4) · Oral (IV form withdrawn US 2009 due to fatal toxicity reports) (1) · rectal (1)

None (86) · 30–60 minutes (1) · Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Symptomatic improvement 2-4 weeks (1)

None (86) · 24 hours (most ER formulations) (1) · 8–12 hours (1) · Chronic daily dosing (1) · Hours per dose (1) · Long (1)

None (86) · 3–5 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"' (1) · ~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)

None (86) · 70–90% (oral) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1) · ~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' (1) · ~50% (highly variable) (1)

None (86) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Not established (1) · Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (86) · Rx-only (1) · Rx-only in US (1) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 91 results in range #1 to #91.

1

2

4

5

5-MeO-DALT

A

B

C

D

E

H

Hawaiian Baby Woodrose

I

L

LSH
LSZ

M

N

Nefazodone

P

R

Reboxetine

S

T

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"